Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab with Long-course Chemoradiotherapy for Rectal Cancer
NCT06304545Phase 2Not yet recruiting
- Sponsor
- Harbin Medical University
- Start
- Mar 2024
- Primary completion
- Aug 2026
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of camrelizumab in rectal cancer, sponsored by Harbin Medical University. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06304545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06304545.